Evommune licenses EVO570, an oral VAV1 molecular glue degrader, from Hinova in a deal worth up to $1.1 billion, with Phase 1 testing expected imminently.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Evommune and Hinova Pharmaceuticals announced on November 4, 2026, an exclusive licensing agreement granting Evommune worldwide rights, excluding Greater China, to develop, manufacture and commercialize EVO570, an oral molecular glue degrader (MGD) targeting VAV1. Formerly designated HC118 and known as HP570 in Greater China, the investigational candidate is expected to enter Phase 1 clinical development imminently. Evommune also plans to initiate a Phase 2 trial in rheumatoid arthritis (RA) in 2027.
EVO570: An Oral VAV1-Directed Protein Degrader
EVO570 uses a molecular glue degradation approach rather than conventional enzyme inhibition. It is designed to direct VAV1 towards the cell’s protein-disposal machinery, resulting in degradation of the target protein.
VAV1 is a guanine nucleotide exchange factor that transmits signals from T-cell and B-cell receptors, supporting immune-cell activation, cytokine production and migration. Its role in lymphocyte signalling makes it a potential target for conditions driven by abnormal immune activation.
According to Evommune, preclinical studies demonstrated activity in animal models of multiple immune-mediated conditions and greater potency in human immune cells than competing VAV1 degraders. The company’s Chief Scientific Officer, Dr. Jeegar Patel, also highlighted a differentiated molecular scaffold and structure-guided optimization associated with sub-nanomolar potency, high selectivity and a pharmacological profile supporting once-daily oral dosing.
These findings remain preclinical and have not yet been validated in patients.
VAV1 Degradation Offers a Potential Alternative to JAK Inhibition
The therapeutic rationale for EVO570 centres on the distribution and biological function of VAV1. Unlike JAK enzymes, which are broadly expressed across multiple tissues and organs, VAV1 is largely restricted to immune cells. Evommune believes this distinction could allow selective modulation of T- and B-cell signalling while potentially limiting effects on non-immune tissues.
This provides a rationale for investigating VAV1 degradation in RA and other autoimmune diseases. However, a more favorable safety and tolerability profile compared with JAK inhibitors remains a hypothesis rather than an established clinical advantage. The extent of target degradation, its duration and its effects on normal immune function will be important determinants of the candidate’s therapeutic potential.
Clinical Development and Regulatory Status
EVO570 remains investigational and has not been approved by any regulatory authority. Investigational New Drug (IND) applications have been submitted in China and accepted in the United States, enabling progression towards clinical testing.
The planned Phase 1 study will evaluate safety, pharmacokinetics and target engagement/pharmacodynamics. Evommune expects to advance the candidate into a Phase 2 trial in RA in 2027.
$30 Million Upfront Payment and Up to $1.1 Billion in Milestones
Under the agreement, Evommune will pay Hinova $30 million upfront, comprising $20 million in cash and $10 million in pre-funded warrants to purchase Evommune common stock. Hinova is also eligible to receive up to $1.07 billion in contingent development, regulatory and commercial milestones, including $150 million in development and regulatory milestones and $920 million in commercial milestones. The agreement additionally provides for tiered royalties on net sales outside Greater China.
Evommune receives exclusive, sublicensable rights across human and animal indications outside mainland China, Hong Kong, Macau and Taiwan, where Hinova retains development and commercialization rights. The transaction provides Evommune access to a new immunology-focused mechanism while allowing Hinova to retain its regional commercial interests.
Clinical Interpretation: Human Target Engagement Will Be the First Test
The licensing agreement represents a pipeline-expansion transaction rather than a clinical validation of VAV1 degradation. Its significance lies in Evommune’s entry into a distinct immunological mechanism with potential applications across T- and B-cell-driven autoimmune diseases.
The first critical development milestone will be demonstrating that oral administration produces meaningful VAV1 degradation and sustained target engagement in humans without unacceptable effects on immune function. Subsequent Phase 2 results in RA will determine whether the preclinical pharmacological profile translates into meaningful clinical activity.
For now, EVO570 offers a differentiated approach to autoimmune disease research, but its efficacy and potential safety advantages over established therapies remain to be demonstrated.
Reference
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals, Evommune, 04 November 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.